suramin has been researched along with Rhabdomyosarcoma in 4 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Rhabdomyosarcoma: A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin is a polysulfonated naphthyl-urea with antineoplastic activity that binds various peptide growth factors." | 5.28 | Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. ( Helman, LJ; Maggi, M; Minniti, CP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minniti, CP | 2 |
| Helman, LJ | 2 |
| De Giovanni, C | 1 |
| Melani, C | 1 |
| Nanni, P | 1 |
| Landuzzi, L | 1 |
| Nicoletti, G | 1 |
| Frabetti, F | 1 |
| Griffoni, C | 1 |
| Colombo, MP | 1 |
| Lollini, PL | 1 |
| Arnold, HH | 1 |
| Salminen, A | 1 |
| Maggi, M | 1 |
1 review available for suramin and Rhabdomyosarcoma
| Article | Year |
|---|---|
IGF-II in the pathogenesis of rhabdomyosarcoma: a prototype of IGFs involvement in human tumorigenesis.
Topics: Adult; Carrier Proteins; Cell Division; Cell Movement; Embryo, Mammalian; Exons; Gene Expression; Hu | 1993 |
3 other studies available for suramin and Rhabdomyosarcoma
| Article | Year |
|---|---|
Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin.
Topics: Base Sequence; Cell Differentiation; Cell Division; Humans; Molecular Sequence Data; Rhabdomyosarcom | 1995 |
Differentiation of BA-HAN-1C rhabdomyosarcoma cells is controlled by a pertussis toxin sensitive signaling pathway.
Topics: Adenosine Diphosphate; Animals; Cell Differentiation; Cell Transformation, Neoplastic; Cyclic AMP; F | 1993 |
Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop.
Topics: Antineoplastic Agents; Binding, Competitive; Cell Division; Cell Line; Humans; Insulin-Like Growth F | 1992 |